PNV 3.57% $2.43 polynovo limited

Ann: PolyNovo Awarded BARDA Contract for Burns Trial, page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 5,270 Posts.
    lightbulb Created with Sketch. 244
    Initial phase value of contract is US$8.2 million for 10 patient clinical trial, which if showing successful outcomes may be followed at BARDA’s discretion by a US$18 million 150 patient trial, which if successful will lead to a fully funded PMA pathway to FDA approval valued at a further US$26 Million. Total potential value: US$52.2 million over perhaps 3-4 years. Not bad.
    Last edited by jevalent: 29/09/15
 
watchlist Created with Sketch. Add PNV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.